Edwards Lifesciences Corp
Change company Symbol lookup
Select an option...
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF
Go

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Closing Price
$87.87
Day's Change
0.38 (0.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
88.15
Day's Low
86.84
Volume
(Heavy Day)
Volume:
3,128,902

10-day average volume:
2,258,643
3,128,902

Alaska Air sees travel demand declining in November, and cash burn increasing

6:38 am ET November 19, 2020 (MarketWatch)
Print

Shares of Alaska Air Group Inc. (ALK) slipped 0.3% in premarket trading Thursday, after the air carrier provided a downbeat outlook for November, in which traffic and load factor are expected to decline from October while cash burn increases. The company said October total revenue fell 62% from a year ago after a 66% decline in September, and expects a decline of 60% to 65% in November. While October revenue passengers increased to 1,400 (down 64%) from 1,212 (down 68%) from September, passengers are expected to decline to 1,200 to 1,300 (down 65% to 70%) in November. Load factor improved from 47% in September to 49% in October, but is expected to decline to 40% to 45% in November. October cash burn was 97% million, which was lower than September because of improved ticket sales, but cash burn for November is expected to increase to $125 million to $150 million amid a softening in demand. "We believe that renewed restrictions by many state and local governments have negatively impacted demand in the immediate term," the company said in a statement. "Future booking patterns remain difficult to predict given continued uncertainty in COVID-19 cases and timing of available vaccines and treatments."

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 19, 2020 06:38 ET (11:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.